Destiny Pharma PLC - clinical stage biotechnology company based in Brighton, England - Says Chief Scientific Officer Bill Love has joined the UK Research and Innovation Covid-19 Research and Innovation Taskforce.
Destiny is currently developing with SporeGen Ltd, a biotherapeutic product SPOR-COV for the prevention of Covid-19 and other viral respiratory infections. SPOR-COV utilises the innate immune system with the aim of developing Covid-19 protection within a few days after dosing, it says.
Love says: "I am honoured to join the UKRI Taskforce, created to focus on the strength and creativity of the UK's world-class research base. I look forward to supporting UKRI in the identification of research and innovation projects to tackle this significant challenge worldwide."
Current stock price: 102.50 pence
Year-to-date change: up 50%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Destiny Pharma. (DEST)